**PROMPT:**

Assessment / Plan: 56 year old patient with history of AML without CNS involvement who is status post successful 7+3 induction therapy being admitted for acute myocardial infarction

**RESPONSE (Sentence ending after 60th word):**

on day 2 and has been previously prescribed valproate. On admission, was given daclizumab as monotherapy, with doses of 300 mg/day for 1 day followed by 300 mg/day divided into 3 doses daily for 13 days for treatment of early phase hypertension. During the initial 5-day observation period, it was noted that there were no significant safety concerns, that there were no obvious clinical findings that might be potentially suggestive of CNS toxicity, and there were no other significant side effect profiles that would significantly restrict the patient's ability to participate in future care. 